A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response

Some human immunodeficiency virus (HIV)-infected individuals are not able to achieve a normal CD4(+) T cell count despite prolonged, treatment-mediated viral suppression. We conducted an intensification study to assess whether residual viral replication contributes to replenishment of the latent res...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Journal of infectious diseases Ročník 203; číslo 7; s. 960
Hlavní autori:	Hatano, Hiroyu, Hayes, Timothy L, Dahl, Viktor, Sinclair, Elizabeth, Lee, Tzong-Hae, Hoh, Rebecca, Lampiris, Harry, Hunt, Peter W, Palmer, Sarah, McCune, Joseph M, Martin, Jeffrey N, Busch, Michael P, Shacklett, Barbara L, Deeks, Steven G
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.04.2011
Predmet:	ADP-ribosyl Cyclase 1 - analysis Anti-HIV Agents - administration & dosage Anti-HIV Agents - adverse effects CD4 Lymphocyte Count CD4-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - chemistry CD8-Positive T-Lymphocytes - immunology HIV Infections - drug therapy HLA-DR Antigens - analysis Humans Membrane Glycoproteins - analysis Placebos - administration & dosage Pyrrolidinones - administration & dosage Pyrrolidinones - adverse effects Raltegravir Potassium T-Lymphocyte Subsets - immunology Treatment Outcome Viral Load Viremia
ISSN:	1537-6613, 1537-6613
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Some human immunodeficiency virus (HIV)-infected individuals are not able to achieve a normal CD4(+) T cell count despite prolonged, treatment-mediated viral suppression. We conducted an intensification study to assess whether residual viral replication contributes to replenishment of the latent reservoir and whether mucosal HIV-specific T cell responses limit the reservoir size. Thirty treated subjects with CD4(+) T cell counts of <350 cells/mm(3) despite viral suppression for ≥ 1 year were randomized to add raltegravir (400 mg twice daily) or matching placebo for 24 weeks. The primary end points were the proportion of subjects with undetectable plasma viremia (determined using an ultrasensitive assay with a lower limit of detection of <.3 copy/mL) and a change in the percentage of CD38(+)HLA-DR(+)CD8(+) T cells in peripheral blood mononuclear cells (PBMCs). The proportion of subjects with undetectable plasma viremia did not differ between the 2 groups (P = .42). Raltegravir intensification did not have a significant effect on immune activation or HIV-specific responses in PBMCs or gut-associated lymphoid tissue. Low-level viremia is not likely to be a significant cause of suboptimal CD4(+) T cell gains during HIV treatment. NCT00631449.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	1537-6613 1537-6613
DOI:	10.1093/infdis/jiq138